Below are the most recent publications written about "Butyrates" by people in Profiles.
-
Lobel L, Garrett WS. Butyrate Makes Macrophages "Go Nuclear" against Bacterial Pathogens. Immunity. 2019 02 19; 50(2):275-278.
-
Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, Ginsberg H, Hiatt WR, Ishibashi S, Koenig W, Nordestgaard BG, Fruchart JC, Libby P, Ridker PM. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018 12; 206:80-93.
-
Verma MS, Fink MJ, Salmon GL, Fornelos N, Ohara TE, Ryu SH, Vlamakis H, Xavier RJ, Stappenbeck TS, Whitesides GM. A Common Mechanism Links Activities of Butyrate in the Colon. ACS Chem Biol. 2018 05 18; 13(5):1291-1298.
-
Byndloss MX, Olsan EE, Rivera-Chávez F, Tiffany CR, Cevallos SA, Lokken KL, Torres TP, Byndloss AJ, Faber F, Gao Y, Litvak Y, Lopez CA, Xu G, Napoli E, Giulivi C, Tsolis RM, Revzin A, Lebrilla CB, Bäumler AJ. Microbiota-activated PPAR-? signaling inhibits dysbiotic Enterobacteriaceae expansion. Science. 2017 08 11; 357(6351):570-575.
-
Jiang S, Xie S, Lv D, Wang P, He H, Zhang T, Zhou Y, Lin Q, Zhou H, Jiang J, Nie J, Hou F, Chen Y. Alteration of the gut microbiota in Chinese population with chronic kidney disease. Sci Rep. 2017 06 06; 7(1):2870.
-
Ananthakrishnan AN, Luo C, Yajnik V, Khalili H, Garber JJ, Stevens BW, Cleland T, Xavier RJ. Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. Cell Host Microbe. 2017 May 10; 21(5):603-610.e3.
-
Torii K, Maeshige N, Aoyama-Ishikawa M, Miyoshi M, Terashi H, Usami M. Combination therapy with butyrate and docosahexaenoic acid for keloid fibrogenesis: an in vitro study. An Bras Dermatol. 2017 Mar-Apr; 92(2):184-190.
-
Honda Y, Kessoku T, Ogawa Y, Tomeno W, Imajo K, Fujita K, Yoneda M, Takizawa T, Saito S, Nagashima Y, Nakajima A. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep. 2017 02 14; 7:42477.
-
Kind T, Cho E, Park TD, Deng N, Liu Z, Lee T, Fiehn O, Kim J. Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. Sci Rep. 2016 12 15; 6:39227.
-
Satitsri S, Pongkorpsakol P, Srimanote P, Chatsudthipong V, Muanprasat C. Pathophysiological mechanisms of diarrhea caused by the Vibrio cholerae O1 El Tor variant: an in vivo study in mice. Virulence. 2016 10 02; 7(7):789-805.